Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy

Schizophrenia Research

Volumn 148, Issue 1-3, 2013, Pages 59-66

  Tandon, Neeraj ^a   Bolo, Nicolas R ^a   Sanghavi, Kunal ^a   Mathew, Ian T ^a   Francis, Alan N ^a   Stanley, Jeffrey A ^b   Keshavan, Matcheri S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Early psychosis; High risk; Schizophrenia; Spectroscopy

Indexed keywords

CHOLINE; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID;

ADOLESCENT; ADULT; ANTERIOR CINGULATE; ARTICLE; BRAIN LEVEL; BRAIN METABOLISM; BRAIN REGION; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FAMILY STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RISK ASSESSMENT; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; THALAMUS;

EARLY PSYCHOSIS; HIGH RISK; SCHIZOPHRENIA; SPECTROSCOPY;

ADOLESCENT; ANALYSIS OF VARIANCE; ASPARTIC ACID; BRAIN; COGNITION DISORDERS; FAMILY HEALTH; FEMALE; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84881023457     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.05.024     Document Type: Article

References (64)

1. Abbott C., Bustillo J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr. Opin. Psychiatry 2006, 19:135-139.
2. Bhojraj T.S., Sweeney J.A., Prasad K.M., et al. Longitudinal alterations of executive function in non-psychotic adolescents at familial risk for schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:469-474.
3. Bhojraj T.S., Sweeney J.A., Prasad K.M., et al. Gray matter loss in young relatives at risk for schizophrenia: relation with prodromal psychopathology. NeuroImage 2011, 54(Suppl.1):S272-S279.
4. Borgwardt S.J., McGuire P.K., Aston J., et al. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br. J. Psychiatry Suppl. 2007, 51:68-75.
5. Bottomley P.A., Foster T.H., Leue W.M. In vivo nuclear magnetic resonance chemical shift imaging by selective irradiation. Proc. Natl. Acad. Sci. 1984, 81:6856-6860.
6. Brugger S., Davis J.M., Leucht S., Stone J.M. Proton magnetic resonance spectroscopy and illness stage in schizophrenia - a systematic review and meta-analysis. Biol. Psychiatry 2011, 69:495-503.
7. Capizzano A.A., Toscano J.L.N., Ho B.-C. Magnetic resonance spectroscopy of limbic structures displays metabolite differences in young unaffected relatives of schizophrenia probands. Schizophr. Res. 2011, 131:4-10.
8. Catani M., Cherubini A., Howard R., et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001, 12:2315-2317.
9. Chapman L.J., Chapman J.P., Raulin M.L. Body image aberration in schizophrenia. J. Abnorm. Psychol. 1978, 87:399-407.
10. Clinton S.M., Meador-Woodruff J.H. Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in-vivo imaging abnormalities. Schizophr. Res. 2004, 69:237-253.
11. Dale A., Fischl B., Sereno M. Cortical surface-basedanalysis. 1. Segmentation and surface reconstruction. NeuroImage 1999, 9:179-194.
12. de la Fuente-Sandoval C., Leon-Ortiz P., Favila R., et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011, 36:1781-1791.
13. Di Costanzo A., Trojsi F., Tosetti M., et al. High-field proton MRS of human brain. Eur. J. Radiol. 2003, 48:146-153.
14. Erlenmeyer-Kimling L., Squires-Wheeler E., Adamo U.H., et al. The New York High-Risk Project. Psychoses and cluster A personality disorders in offspring of schizophrenic parents at 23years of follow-up. Arch. Gen. Psychiatry 1995, 52:857-865.
15. Ernst T., Kreis R., Ross B.D. Absolute quantitation of water and metabolites in the human brain. 1. Compartments and water. J. Magn. Reson. B 1993, 102:1-8.
16. Fischl B., Salat D.H., Busa E., et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
17. Fusar-Poli P., Borgwardt S., Bechdolf A., et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70:107-120.
18. 1H magnetic resonance spectroscopy in healthy aging. Neurobiol. Aging 2009, 30:353-363.
19. 1H-MR spectroscopy in the evaluation of epilepsies - what do pathological spectra stand for?. Acta Neurol. Scand. 2003, 108:223-238.
20. Heaton R., Chelune G., Talley J., et al. Wisconsin Card Sorting Test Manual: Revised and Expanded. Psychological Assessment resources, Odessa, Florida 1993.
21. Helms G. The principles of quantification applied to in vivo proton MR spectroscopy. Eur. J. Radiol. 2008, 67:218-229.
22. 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 2006, 240:318-332.
23. Jessen F., Scherk H., Traber F., et al. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr. Res. 2006, 87:81-88.
24. Kaufman J., Schweder A.E. The Schedule for Affective Disorders and Schizophrenia for school-age children: present and life-time version (K-SADS-PL). Comprehensive Textbook of Psychological Assessment 2003, vol. 2:247-255. John Wiley and Sons, New York.
25. Keshavan M.S., Montrose D.M., Pierri J.N., Dick E.L., Rosenberg D., Talagala L., Sweeney J.A. Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: preliminary studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 1997, 21:1285-1295.
26. Keshavan M.S., Tandon R., Boutros N., Nasrallah H.A. Schizophrenia, "just the facts" 3. Neurobiology and pathophysiology. Schizophr. Res. 2008, 106:89-107.
27. 1H spectroscopic study. Schizophr. Res. 2009, 115:88-93.
28. Kim K.R., Park J.Y., Song D.-H., et al. Neurocognitive performance in subjects at high risk for schizophrenia: a comparison with first-episode schizophrenia. Compr. Psychiatry 2011, 52:33-40.
29. Kuperberg G.R., Broome M.R., McGuire P.K., et al. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60:878-888.
30. Kwapil T.R., Barrantes-Vidal N., Silvia P.J. The dimensional structure of the Wisconsin Schizotypy Scales: factor identification and construct validity. Schizophr. Bull. 2008, 34:444-457.
31. Lawrie S.M., McIntosh A.M., Hall J., et al. Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr. Bull. 2008, 34:330-340.
32. Lenzenweger M.F. Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: an update. Schizophr. Bull. 1994, 20:121-135.
33. Liu S., Deng W., Huang X., et al. Neuroanatomical differences between familial and sporadic schizophrenia and their parents: an optimized voxel-based morphometry study. Psychiatry Res. 2009, 171:71-81.
34. 1H-MRS studies. Schizophr. Bull. 2013, 39:120-129.
35. McIntosh A.M., Owens D.G.C., Moorhead W.J., et al. Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. Biol. Psychiatry 2011, 69:953-958.
36. Meisenzahl E.M., Koutsouleris N., Gaser C., et al. Structural brain alterations in subjects at high risk of psychosis: a voxel-based morphometric study. Schizophr. Res. 2008, 102:150-162.
37. Miller T.J., McGlashan T.H., Rosen J.L. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of inter-rater reliability and predictive validity. Am. J. Psychiatry 2002, 159:863-865.
38. Moffett J.R., Ross B., Arun P., et al. N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 2007, 81:89-131.
39. 1HMRS) of the hippocampal formation in schizophrenia. Br. J. Psychiatry 1994, 165:484-489.
40. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30:672-679.
41. Purdon S.E., Valiakalayil A., Hanstock C.C., et al. Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-OX) scores and genetic risk for schizophrenia. Schizophr. Res. 2008, 99:218-224.
42. 1H magnetic resonance spectroscopy study. Acta Radiol. 2010, 51:309-315.
43. Shirayama Y., Obata T., Matsuzawa D., et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits of schizophrenia. NeuroImage 2010, 49:2783-2790.
44. Sibson N.R., Dhankhar A., Mason G.F., Rothman D.L., Behar K.L., Shulman R.G. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(1). (316 C321).
45. Smieskova R., Fusar-Poli P., Allen P., et al. Neuroimaging predictors of transition to psychosis - a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 2010, 34:1207-1222.
46. Smith S.M., Jenkison M., Woolrich M.W., et al. Advances in functional and structural MR analysis and implementation as FSL. NeuroImage 2004, 23(Suppl.1):208-219.
47. Spitzer R.L., Williams J.B., Gibbons M., First M.B. The Structured Clinical Interview for DSM (SCID). 1. History, rationale, and description. Arch. Gen. Psychiatry 1992, 49:624-629.
48. 1H MR spectra. Magn. Reson. Med. 1995, 34:17-24.
49. 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005, 30:1949-1962.
50. Stone J.M., Day F., Tsagaraki H., et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatry 2009, 66:533-539.
51. Stone J.M., Howes O.D., Eggerton A., et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra-high risk of psychosis. Biol. Psychiatry 2010, 68:599-602.
52. Tae W.S., Kim S.S., Lee K.U., et al. Validation of hippocampal volumes measured using a manual method and two automated methods (FreeSurfer and IBASPM) in chronic major depressive disorder. Neuroradiology 2008, 50:569-581.
53. Tandon R., Carpenter W.T. DSM-5 status of psychotic disorders: 1-year pre-publication. Schizophr. Bull. 2012, 38:369-370.
54. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "just the facts". What we know in 2008, 2 Epidemiology and etiology. Schizophr. Res. 2008, 102:1-18.
55. Tandon N., Montrose D., Shah J., et al. Early prodromal symptoms can predict future psychosis in familial high-risk youth. J. Psychiatr. Res. 2012, 46:105-110.
56. Tandon N., Shah J., Keshavan M.S., Tandon R. Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention. Neuropsychiatry 2012, 2:345-353.
57. Theberge J., Williamson K.E., Aoyama N., et al. Longitudinal grey matter and glutamatergic losses in first-episode schizophrenia. Br. J. Psychiatry 2007, 191:325-334.
58. Tibbo P., Hanstock C., Valiakalayil A., Allen P. 3_T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am. J. Psychiatry 2004, 161:1116-1118.
59. 1H-MR spectroscopy in ultra-high risk and first episode stages of schizophrenia. J. Psychiatr. Res. 2011, 45:1135-1139.
60. Whyte M.C., Brett C., Harrison L.K., et al. Neuropsychological performance over time in people at high risk for developing schizophrenia and controls. Biol. Psychiatry 2006, 59:730-739.
61. Wood S.J., Berger G.E., Veliakoulis D., et al. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high risk individuals. Schizophr. Bull. 2003, 29:831-843.
62. Wood S.J., Yung A.R., McGorry P.D., Pantelis C. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biol. Psychiatry 2011, 70:619-625.
63. Yoo S.Y., Yeon S., Choi C.-H., et al. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr. Res. 2009, 111:86-93.
64. Zhao Q., Patriotis P., Arias-Mendoza F., Stoyanova R., Brown T. An interactive software for 3D chemical shift imaging data analysis and real time spectral localization and quantification. Proc. Int. Soc. Magn. Reson. Med. 2005, 13:2465.